Milestone Pharmaceuticals Inc. (MIST) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines, primarily its lead product candidate, etripamil (CARDAMYST), a rapid-onset nasal spray for paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates as a single segment and is currently pre-revenue.
Key Financial Metrics
| Metric (in thousands USD) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(11,922) | $(9,439) | $(45,649) | $(29,156) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.14) | $(0.60) | $(0.48) |
| Cash & Cash Equivalents | $46,685 | $12,799 | $46,685 | $12,799 |
| Short-term Investments | $35,900 | $44,381 | $35,900 | $44,381 |
| Total Liquidity (Cash + ST Inv) | $82,585 | $57,180 | $82,585 | $57,180 |
| Senior Secured Convertible Notes | $56,206 | $53,352 | $56,206 | $53,352 |
| Accumulated Deficit | $(413,194) | $(355,182) | $(413,194) | $(355,182) |
Material Changes vs. Prior Period
- Commercial Expenses Surge: Commercial expenses increased by 142.1% in Q3 2025 ($4.6M) compared to Q3 2024 ($1.9M), and by 204.8% for the nine-month period. This reflects preparation for the potential launch of CARDAMYST, though the company temporarily paused ramping up operational expenditures following a Complete Response Letter (CRL) from the FDA.
- Net Loss Expansion: Net loss increased by 26.3% in Q3 2025 and 56.6% for the nine months ended September 30, 2025, driven primarily by higher commercial and R&D costs.
- Capital Raise: In July 2025, the company completed an underwritten public offering (the "2025 Offering") raising net proceeds of approximately $48.6 million through the sale of common shares, pre-funded warrants, and Series A and B warrants.
- Debt Accretion: The carrying value of Senior Secured Convertible Notes increased due to the accrual of paid-in-kind (PIK) interest.
Guidance, Outlook, and Risks
- Regulatory Status (PSVT): In March 2025, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CARDAMYST for PSVT. The CRL cited Chemistry, Manufacturing, and Controls (CMC) issues regarding nitrosamine impurities and a required facility inspection. The company submitted a response in June 2025, which was accepted, resulting in a new PDUFA target date of December 13, 2025.
- Regulatory Status (AFib-RVR): The company is preparing a Phase 3 program for AFib-RVR but has delayed enrollment pending the resolution of the PSVT NDA.
- Liquidity Outlook: Management expects current cash, cash equivalents, and short-term investments ($82.6 million) to be sufficient to fund operations for at least the next 12 months.
- Royalty Purchase Agreement: The company has an agreement with RTW Investments to sell a royalty interest in U.S. sales of etripamil for $75.0 million, contingent on FDA approval by December 31, 2025 (extended from September 30, 2025).
- Risks: Key risks include the uncertainty of FDA approval following the CRL, the need for additional financing if approval is delayed, and potential impacts from international trade policies and tariffs on supply chains.
Investor Verification Checklist
- Verify the status of the FDA's review of the response to the CRL and the likelihood of meeting the December 13, 2025 PDUFA date.
- Confirm the specific CMC remediation steps taken regarding nitrosamine impurities and the facility inspection results.
- Monitor the burn rate and cash runway, specifically how the pause in commercial ramp-up affects the 12-month liquidity projection.
- Review the terms of the Royalty Purchase Agreement with RTW, specifically the conditions required to trigger the $75 million payment.
- Assess the dilution impact of the July 2025 offering and the outstanding warrants (Series A and B) on future share counts.